Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B vaccine (University of North Carolina, Chapel Hill)
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The hepatitis B vaccine (University of North Carolina, Chapel Hill) refers to the recombinant hepatitis B vaccine utilized in clinical research led by the University of North Carolina at Chapel Hill, specifically focusing on birth-dose administration in the Democratic Republic of the Congo (DRC). The vaccine consists of hepatitis B surface antigen (HBsAg) and is designed to induce active immunity against the hepatitis B virus (HBV). In the context of the UNC-led studies, the vaccine is evaluated for its immunogenicity and ability to prevent mother-to-child transmission when administered within the first 24 hours of life to both HBV-exposed and unexposed infants. The research aims to support the universal adoption of a birth-dose vaccine schedule in sub-Saharan Africa.
- Other names
- Birth dose hepatitis B vaccineHBV vaccinehepatitis B vaccine-University of North Carolina, Chapel Hill-Hepatitis B
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B vaccine (University of North Carolina, Chapel Hill).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B vaccine (University of North Carolina, Chapel Hill).